Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance) Academic Article uri icon

Overview

MeSH Major

  • Lymphoma, Follicular
  • Rituximab
  • Thalidomide

abstract

  • LR is more active than lenalidomide alone in recurrent FL with similar toxicity, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel agents.

publication date

  • November 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4622102

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.59.9258

PubMed ID

  • 26304886

Additional Document Info

start page

  • 3635

end page

  • 40

volume

  • 33

number

  • 31